Compare BCRX & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | ENOV |
|---|---|---|
| Founded | 1986 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1994 | 2008 |
| Metric | BCRX | ENOV |
|---|---|---|
| Price | $7.20 | $27.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $20.08 | ★ $49.14 |
| AVG Volume (30 Days) | ★ 4.0M | 854.1K |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $599,816,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $40.20 | $9.27 |
| Revenue Next Year | $7.71 | $4.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.38 | 11.57 |
| 52 Week Low | $6.00 | $25.47 |
| 52 Week High | $11.31 | $49.38 |
| Indicator | BCRX | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 44.70 |
| Support Level | $7.23 | $25.52 |
| Resistance Level | $7.92 | $28.27 |
| Average True Range (ATR) | 0.35 | 1.25 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 13.42 | 36.04 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.